BR0010256A - Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários - Google Patents

Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários

Info

Publication number
BR0010256A
BR0010256A BR0010256-3A BR0010256A BR0010256A BR 0010256 A BR0010256 A BR 0010256A BR 0010256 A BR0010256 A BR 0010256A BR 0010256 A BR0010256 A BR 0010256A
Authority
BR
Brazil
Prior art keywords
compound
treatment
carboxypeptidase
inhibition
preparation
Prior art date
Application number
BR0010256-3A
Other languages
English (en)
Inventor
Marcel Linschoten
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0010256A publication Critical patent/BR0010256A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODO DE TRATAMENTO OU PROFILAXIA DE CONDIçõES ASSOCIADAS COM A INIBIçãO DA CARBOXIPEPTIDASE U, KIT DE PARTES, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE OU SUSCEPTìVEL A UMA CONDIçãO EM QUE A INIBIçãO DA CARBOXIPEPTIDASE U E UM MECANISMO ANTITROMBóTICO DIFERENTE SãO NECESSáRIOS A presente invenção refere-se a compostos de Fórmula (I) e a seus sais ou solvatos farmaceuticamente aceitáveis, ou solvatos de tais sais, compostos estes inibindo a carboxipeptidase U e, assim, podendo ser usados na prevenção e tratamento de doenças associadas com a carboxipeptidase U. Em outros aspectos, a invenção refere-se a compostos da invenção para uso em terapia; a processos para preparação de tais novos compostos; a composições farmacêuticas contendo pelo menos um composto da invenção, ou um seu sal ou solvato farmaceuticamente aceitável, como ingrediente ativo; e ao uso dos compostos ativos na manufatura de medicamentos para o uso médico indicado acima.
BR0010256-3A 1999-05-03 2000-05-03 Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários BR0010256A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds
PCT/SE2000/000846 WO2000066550A1 (en) 1999-05-03 2000-05-03 New compounds

Publications (1)

Publication Number Publication Date
BR0010256A true BR0010256A (pt) 2002-02-13

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010256-3A BR0010256A (pt) 1999-05-03 2000-05-03 Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários

Country Status (23)

Country Link
US (2) US7354895B1 (pt)
EP (1) EP1180099A1 (pt)
JP (1) JP4270759B2 (pt)
KR (1) KR20020010631A (pt)
CN (1) CN1358187A (pt)
AR (1) AR028826A1 (pt)
AU (1) AU4447100A (pt)
BR (1) BR0010256A (pt)
CA (1) CA2371215A1 (pt)
CZ (1) CZ20013931A3 (pt)
EE (1) EE200100573A (pt)
HK (1) HK1042493A1 (pt)
HU (1) HUP0202379A3 (pt)
IL (1) IL145953A0 (pt)
IS (1) IS6141A (pt)
MX (1) MXPA01011043A (pt)
NO (1) NO20015374D0 (pt)
PL (1) PL356140A1 (pt)
SE (1) SE9901572D0 (pt)
SK (1) SK15662001A3 (pt)
TR (1) TR200103144T2 (pt)
WO (1) WO2000066550A1 (pt)
ZA (2) ZA200108967B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2202171T3 (es) * 1999-09-14 2004-04-01 Meiji Seika Kaisha, Ltd. Derivados del acido fosfonico que poseen actividad inhibidora de la carboxipeptidas b.
SI1311488T1 (sl) * 2000-08-17 2010-01-29 Pfizer Ltd Substituirani imidazoli kot inhibitorji TAFIA
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
AP2004003084A0 (en) * 2002-01-22 2004-09-30 Pfizer 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP2204373A1 (en) 2002-03-21 2010-07-07 Bayer Schering Pharma Aktiengesellschaft Phosphonic acid as Plasma Carboxypeptidase B Inhibitors
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
BR9206941A (pt) * 1991-12-17 1995-05-02 Procter & Gamble Pharma Métodos para o tratamento da osteoporose usando-se bifosfonatos e hormônio paratireóideo
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
EA003836B1 (ru) 1997-02-27 2003-10-30 Американ Цианамид Компани N-гидрокси-2-(алкил, арил или гетероарилсульфанил, сульфинил или сульфонил)-3-замещенный алкил, арил или гетероариламиды в качестве ингибиторов матричной металлопротеиназы
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
ES2202171T3 (es) * 1999-09-14 2004-04-01 Meiji Seika Kaisha, Ltd. Derivados del acido fosfonico que poseen actividad inhibidora de la carboxipeptidas b.

Also Published As

Publication number Publication date
ZA200108966B (en) 2003-01-30
NO20015374L (no) 2001-11-02
EE200100573A (et) 2003-02-17
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01
CZ20013931A3 (cs) 2002-04-17
AU4447100A (en) 2000-11-17
TR200103144T2 (tr) 2004-11-22
EP1180099A1 (en) 2002-02-20
US20060079484A1 (en) 2006-04-13
AR028826A1 (es) 2003-05-28
ZA200108967B (en) 2003-01-30
MXPA01011043A (es) 2002-06-04
JP2002543179A (ja) 2002-12-17
SK15662001A3 (sk) 2002-09-10
NO20015374D0 (no) 2001-11-02
SE9901572D0 (sv) 1999-05-03
WO2000066550A8 (en) 2001-01-25
KR20020010631A (ko) 2002-02-04
JP4270759B2 (ja) 2009-06-03
CN1358187A (zh) 2002-07-10
HUP0202379A3 (en) 2003-04-28
CA2371215A1 (en) 2000-11-09
WO2000066550A1 (en) 2000-11-09
US7354895B1 (en) 2008-04-08
HK1042493A1 (zh) 2002-08-16
US7423012B2 (en) 2008-09-09
HUP0202379A2 (hu) 2002-12-28
PL356140A1 (en) 2004-06-14

Similar Documents

Publication Publication Date Title
BR0010257A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
BR0214988A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
US4220660A (en) Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents
EP0139534A2 (en) Compositions for the prophylactic treatment of osteitis and osteomyelitis
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
BR0010256A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários
BR0311384A (pt) Composto, processo para preparar o mesmo, formulação farmacêutica, uso de um composto, e, método para tratamento ou profilaxia de condições em que a inibição da carboxipeptidase u é benáfica
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
EP0804185B1 (en) Arsenic medicaments for the treatment of chronic fatigue syndrome
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9915962A (pt) Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento
DE2806866C3 (de) Verwendung von Salzen von Dithiodialkansulfonsäuren
US3128227A (en) Antibiotic intramuscular composition
BR9810214A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, para tratar ou reduzir o risco de doença inflamatória e de dor em uma pessoa sofrendo de ou sob risco de dita doença, de tratamento, e para a preparação de um composto
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
BR9808546A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
BR0016329A (pt) Bis-indolilmaleimidas substituìdas para inibição de proliferação de células
GB2133285A (en) Pharmaceutical compositions
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]